How doctors and abortion advocates are pivoting as mifepristone access shifts
- Medical providers and abortion advocates are preparing for potential shifts in access to medication abortion as the U.S.
- If the court restricts the ability of doctors to mail mifepristone to patients, experts indicate that while barriers to access would increase, it would not entirely stop the...
- Standard medication abortion in the United States typically utilizes a combination of two different medications: mifepristone and misoprostol.
Medical providers and abortion advocates are preparing for potential shifts in access to medication abortion as the U.S. Supreme Court considers a decision on May 11, 2026, regarding the prescription of mifepristone via telehealth.
If the court restricts the ability of doctors to mail mifepristone to patients, experts indicate that while barriers to access would increase, it would not entirely stop the availability of abortion pills through the mail.
Medication Abortion Regimens
Standard medication abortion in the United States typically utilizes a combination of two different medications: mifepristone and misoprostol.
In anticipation of a ruling that could limit the use of mifepristone in telehealth settings, some providers are preparing to pivot to alternative medical protocols.
Dr. Angel Foster, the co-founder of the Massachusetts Medication Abortion Access Project, stated that providers may shift their approach if necessary.
If we have to, we will switch to a misoprostol-only regimen.Dr. Angel Foster
Medical research indicates that using misoprostol alone is a safe and effective method for ending early pregnancy. However, this single-drug regimen may result in a more uncomfortable experience for the patient compared to the combined mifepristone and misoprostol approach.
The Role of Shield Law Providers
The Massachusetts Medication Abortion Access Project operates as a shield law provider. These organizations mail abortion medications to patients across the country, regardless of the specific laws in the patient’s state that may restrict abortion access.
For these providers, the ability to pivot to a misoprostol-only regimen serves as a crucial alternative to ensure continued access to medication abortion in the face of shifting legal regulations.
The outcome of the Supreme Court’s decision on May 11, 2026, will determine whether the current telehealth prescription model for mifepristone remains legal or if providers must rely more heavily on alternative regimens and shield law protections.